New

North America Acute Lung Injury Market

2021

Pharmaceuticals North America Acute Lung Injury Mar...

North America Acute Lung Injury Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapy (Mechanical Ventilation, Fluid Management, Pharmacotherapy, and Adjunctive Procedures) and End User (Hospitals, Ambulatory Surgery Centers, and Others)

Publication Month: Nov 2021 | Report Code: TIPRE00025720 | No. of Pages: 102 | Category: Pharmaceuticals | Status: Published

Market Insights

North America Acute Lung Injury Market to Grow at a CAGR of 4.8% to reach US$ 280.16 million from 2021 to 2028

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!

The North America acute lung injury market is expected to grow from US$ 201.93 million in 2021 to US$ 280.16 million by 2028; it is estimated to grow at a CAGR of 4.8% from 2021 to 2028.

The US, Canada, and Mexico are economies in North America. Growing geriatric population is expected to surge the market growth. The degeneration of various cells or tissues with age leads to a greater risk of multiple diseases. Elderly people are more prone to get affected by the failure of organs such as the lungs, heart, and kidney. This is mainly ascribed to the changes in the composition and metabolic activities in the ecosystem of the aging human body. With the increasing age, the incidence of organ systems efficiency decreases resulting prone to diseases such as respiratory diseases and other infection, thereby driving the target market. Thus, ALI is correlated with increased morbidity and mortality in the aging population. Also, age is generally reported as a risk factor for the growth of ARDS. Countries such as the US and Canada are experiencing significant growth in the geriatric population. The population is aging; over 65s are expected to account for 1 in 6 of the population by 2050, increasing 1 in 11 in 2019. With a strong association between aging and increased incidence of diseases—including respiratory conditions such as chronic obstructive pulmonary disease and acute infection—thorough research on the impact of disease risk and severity will be necessary to manage the health of an ever-aging population effectively. The growth of the geriatric population in these countries is driven by improved healthcare facilities and better healthcare services, which has resulted in increased life expectancy. Thus, the growing aging population is among the major factors for the growth of the North America acute lung injury market.

In case of COVID-19, North America is highly affected especially the US. The high number of COVID cases have resulted in a negative impact on country’s and region’s economy and there has been a decline in overall business activities and growth of various industries operating in the region. Market players are initiated clinical trials for the drug development of acute lung injury. For instance, Chimerix, a biopharmaceutical company initiated a Phase II/III clinical trial in June 2020 for to evaluate the safety and efficacy of Dociparstat sodium (DSTAT) in patients with Acute Lung Injury (ALI) due to COVID-19. DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties. Chimerix completes enrolment in its phase II part of phase II/III trial for acute lung injury. The Phase 2 portion of the study will enroll 24 subjects to confirm the maximum safe dose and then expand it to 50 patients at the selected dose. Contingent upon positive results, the Phase 3 portion of the study will enroll approximately 450 subjects. Furthermore, Altasciences is pleased to support ReAlta Life Sciences by conducting a Phase I trial to evaluate RLS-0071 for treatment of Acute Lung Injury (ALI) as a result of viral infections, such as COVID-19, respiratory syncytial virus (RSV), and influenza. As part of the ReAlta ALI program underway, the Phase I trial is a single-ascending dose, randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK, and PD of RLS-0071 in healthy subjects, performed at the Altasciences clinical pharmacology unit in Montreal, Canada.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America acute lung injury market. The North America acute lung injury market is expected to grow at a good CAGR during the forecast period.

Get more information on this report :


North America Acute Lung Injury Market Segmentation

North America Acute Lung Injury Market – By Therapy

  • Mechanical Ventilation
  • Fluid Management
  • Pharmacotherapy
  • Adjunctive Procedures

North America Acute Lung Injury Market – By End User

  • Hospitals
  • Ambulatory Surgery Centers
  • Others

North America Acute Lung Injury Market, by Country

  • US
  • Canada
  • Mexico

North America Acute Lung Injury Market - Companies Mentioned

  • Angion
  • Asklepion Pharmaceuticals, LLC.
  • GlaxoSmithKline Plc
  • Qx Therapeutics, Inc.
  • ReAlta Life Sciences, Inc.
  • Stemedica Cell Technologies, Inc
  • Windtree Therapeutics, Inc.

TABLE OF CONTENTS

1. Introduction. 13

1.1 Scope of the Study. 13

1.2 The Insight Partners Research Report Guidance. 14

1.3 Market Segmentation. 15

1.3.1 North America Acute Lung Injury Market – By Therapy. 17

1.3.2 North America Acute Lung Injury Market – By End User 17

1.3.3 North America Acute Lung Injury Market– By Country. 17

2. Key Takeaways. 18

3. Research Methodology. 21

3.1 Coverage. 23

3.2 Secondary Research. 23

3.3 Primary Research. 24

4. North America Acute Lung Injury Market– Market Landscape. 25

4.1 Overview.. 25

4.2 North America PEST Analysis. 25

4.3 Experts Opinion. 26

5. North America Acute Lung Injury Market – Key Market Dynamics. 27

5.1 Market Drivers. 27

5.1.1 Rising Prevalence of Respiratory Diseases. 27

5.1.2 Growing Geriatric Population. 28

5.2 Market Restraints. 28

5.2.1 Expensive Therapies. 28

5.3 Market Opportunities. 29

5.3.1 Increasing Technological Advancements by Market Players. 29

5.4 Future Trends. 30

5.4.1 Surging Pipeline Drugs. 30

5.5 Impact Analysis. 30

6. Acute Lung Injury Market– North America Analysis. 32

6.1 North America Acute Lung Injury Market Revenue Forecast and Analysis. 32

7. North America Acute Lung Injury Market Analysis – By Therapy. 34

7.1 Overview.. 34

7.2 North America Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028) 34

7.3 Mechanical Ventilation. 35

7.3.1 Overview.. 35

7.3.2 Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 35

7.4 Fluid Management 37

7.4.1 Overview.. 37

7.4.2 Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 37

7.5 Pharmacotherapy. 39

7.5.1 Overview.. 39

7.5.2 Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 39

7.6 Adjunctive Procedures. 41

7.6.1 Overview.. 41

7.6.2 Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 41

8. North America Acute Lung Injury Market Analysis – By End User 43

8.1 Overview.. 43

8.2 North America Acute Lung Injury Market Revenue Share, by End User (2021 and 2028) 43

8.3 Hospitals. 44

8.3.1 Overview.. 44

8.3.2 Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 44

8.4 Ambulatory Surgery Centers. 46

8.4.1 Overview.. 46

8.4.2 Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 46

8.5 Others. 48

8.5.1 Overview.. 48

8.5.2 Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 48

9. North America Acute Lung Injury Market – Country Analysis. 50

9.1 North America: Acute Lung Injury Market 50

9.1.1 Overview.. 50

9.1.2 North America: Acute Lung Injury Market, by Country, 2021 & 2028 (%) 52

9.1.2.1 US: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million) 53

9.1.2.1.1 US: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million) 54

9.1.2.1.2 US Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million) 55

9.1.2.1.3 US Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million) 55

9.1.2.2 Canada: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million) 57

9.1.2.2.1 Canada: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million) 57

9.1.2.2.2 Canada Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million) 58

9.1.2.2.3 Canada Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million) 59

9.1.2.3 Mexico: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million) 60

9.1.2.3.1 Mexico: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million) 60

9.1.2.3.2 Mexico Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million) 61

9.1.2.3.3 Mexico Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million) 62

10. Impact Of COVID-19 Pandemic on North America Acute Lung Injury Market 63

10.1 North America: Impact Assessment of COVID-19 Pandemic. 63

11. Industry Landscape. 65

11.1 Overview.. 65

11.2 Organic Developments. 65

11.2.1 Overview.. 65

11.3 Inorganic Developments. 67

11.3.1 Overview.. 67

12. Company Profiles. 68

12.1 GlaxoSmithKline Plc. 68

12.1.1 Key Facts. 68

12.1.2 Business Description. 68

12.1.3 Products and Services. 69

12.1.4 Financial Overview.. 69

12.1.5 SWOT Analysis. 72

12.1.6 Key Developments. 73

12.2 Stemedica Cell Technologies, Inc. 74

12.2.1 Key Facts. 74

12.2.2 Business Description. 74

12.2.3 Products and Services. 75

12.2.4 Financial Overview.. 75

12.2.5 SWOT Analysis. 76

12.2.6 Key Developments. 77

12.3 Windtree Therapeutics, Inc. 78

12.3.1 Key Facts. 78

12.3.2 Business Description. 78

12.3.3 Products and Services. 79

12.3.4 Financial Overview.. 79

12.3.5 SWOT Analysis. 81

12.3.6 Key Developments. 82

12.4 ReAlta Life Sciences, Inc. 83

12.4.1 Key Facts. 83

12.4.2 Business Description. 83

12.4.3 Products and Services. 84

12.4.4 Financial Overview.. 84

12.4.5 SWOT Analysis. 85

12.4.6 Key Developments. 86

12.5 Qx Therapeutics, Inc. 87

12.5.1 Key Facts. 87

12.5.2 Business Description. 87

12.5.3 Products and Services. 88

12.5.4 Financial Overview.. 88

12.5.5 SWOT Analysis. 89

12.5.6 Key Developments. 90

12.6 Angion. 91

12.6.1 Key Facts. 91

12.6.2 Business Description. 91

12.6.3 Products and Services. 92

12.6.4 Financial Overview.. 92

12.6.5 SWOT Analysis. 94

12.6.6 Key Developments. 95

12.7 Asklepion Pharmaceuticals, LLC. 96

12.7.1 Key Facts
. 96

12.7.2 Business Description. 96

12.7.3 Products and Services. 97

12.7.4 Financial Overview.. 97

12.7.5 SWOT Analysis. 98

12.7.6 Key Developments. 99

13. Appendix
. 100

13.1 About The Insight Partners. 100

13.2 Glossary of Terms

LIST OF TABLES

Table 1. North America Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million) 33

Table 2. US Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million) 55

Table 3. US Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million) 55

Table 4. Canada Acute Lung Injury Market, by Therapy -Revenue and Forecast to 2028 (USD Million) 58

Table 5. Canada Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million) 59

Table 6. Mexico Acute Lung Injury Market, by Therapy -Revenue and Forecast to 2028 (USD Million) 61

Table 7. Mexico Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million) 62

Table 8. Organic Developments Done by Companies. 66

Table 9. Inorganic Developments Done by Companies. 67

Table 10. Glossary of Terms

LIST OF FIGURES

Figure 1. North America Acute Lung Injury Market Segmentation. 15

Figure 2. North America Acute Lung Injury Market Segmentation, By Country. 16

Figure 3. North America Acute Lung Injury Market Overview.. 18

Figure 4. Mechanical Ventilation Segment Held the Largest Share of the Market in 2021. 19

Figure 5. The US to Show Significant Growth During Forecast Period. 20

Figure 6. North America PEST Analysis. 25

Figure 7. North America Acute Lung Injury Market Impact Analysis of Driver and Restraints. 31

Figure 8. North America Acute Lung Injury Market– Revenue Forecast and Analysis. 32

Figure 9. North America Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028) 34

Figure 10. North America Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 36

Figure 11. North America Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 38

Figure 12. North America Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 40

Figure 13. North America Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 42

Figure 14. North America Acute Lung Injury Market Revenue Share, by End User (2021 and 2028) 43

Figure 15. North America Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 45

Figure 16. North America Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 47

Figure 17. North America Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million) 49

Figure 18. North America: Acute Lung Injury Market, by Key Country – Revenue (2021) (USD Million) 51

Figure 19. North America: Acute Lung Injury Market, by Country, 2021 & 2028 (%) 52

Figure 20. US: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million) 54

Figure 21. Canada: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million) 58

Figure 22. Mexico: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million) 61

Figure 23. Impact of COVID-19 Pandemic in North American Country Markets

  1. Angion
  2. Asklepion Pharmaceuticals, LLC.
  3. GlaxoSmithKline Plc
  4. Qx Therapeutics, Inc.
  5. ReAlta Life Sciences, Inc.
  6. Stemedica Cell Technologies, Inc
  7. Windtree Therapeutics, Inc.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America acute lung injury market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the North America acute lung injury market, thereby allowing players across the value chain to develop effective long-term strategies    
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth North America market trends and outlook coupled with the factors driving the acute lung injury market, as well as those hindering it 
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution  
TIPRE00025720
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.
Contact Us : +1-646-491-9876 | +91-20-67271633 | Email : sales@theinsightpartners.com
© Copyright 2021 - The Insight Partners. All rights reserved